title: Do human lymphocytes exposed to the fallout of the Chernobyl accident exhibit an adaptive response? 2. Challenge with bleomycin.
abstract: The present study concerns the possible adaptive response, induced in vivo by a continuous exposure to ionizing radiations, to a challenge treatment with the radiomimetic glycopeptide bleomycin (BLM). Lymphocytes from children contaminated as a consequence of Chernobyl accident were treated for the last 5 h of culture with 2.5 micrograms/ml BLM. The induced chromosome damage was significantly lower than that found with the same treatment in lymphocytes from control children. This hyposensitivity to BLM was still present if, 1 h after the addition of the drug, inhibitors of the enzymes involved in DNA repair, such as 3-aminobenzamide (2 mM), or aphidicolin (0.4 microM) or 3-dideoxythymidine (5 mM) were added to the cultures. The resistance to BLM in lymphocytes from contaminated children seems to be related to a mechanism upstream in respect to the activities of enzymes involved in the DNA repair and specifically linked to the action of this drug. This is consistent with the different response found when the cells were challenged with ionizing radiation in vitro, as reported in the accompanying paper (L. Padovani, L. et al. (1995) Mutation Res., this issue).
authors.affiliation: Department of Public Health and Cell Biology, University of Rome Tor Vergata, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Tedeschi
authors.forename: D
authors.initials: D
authors.lastname: Caporossi
authors.forename: P
authors.initials: P
authors.lastname: Vernole
authors.forename: L
authors.initials: L
authors.lastname: Padovani
authors.forename: M
authors.initials: M
authors.lastname: Appolloni
authors.forename: P
authors.initials: P
authors.lastname: Anzidei
authors.forename: F
authors.initials: F
authors.lastname: Mauro
mesh_terms: D000222:Adaptation, Physiological / Q000187:drug effects; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology*; D002478:Cells, Cultured; D002648:Child; D002869:Chromosome Aberrations; D004249:DNA Damage / Q000187:drug effects* / Q000528:radiation effects; D004260:DNA Repair / Q000187:drug effects*; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects* / Q000528:radiation effects; D008297:Male; D018788:Radioactive Hazard Release; D014455:Ukraine
chemical_list: D000964:Antimetabolites, Antineoplastic; D001761:Bleomycin